Leukemia and Myelodysplasia Effect of Multiple Cytotoxic Therapy in Essential Thrombocythemia

References

• Cortellazzo S., Finazzi G., Ruggeri M., Vestri O., Galli M., Rodeghiero E, Barbui T. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. New England Journal of Medicine 1995; 332: 1132–1136
   PubMed Web of Science ®Google Scholar
• Rozman C., Giralt M., Feliu E., Rubio D., Cortes M. T. Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663
   PubMed Web of Science ®Google Scholar
• Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia vera Study Group. Seminars Hematology 1986; 23: 177–182
   PubMed Web of Science ®Google Scholar
• Higuchi T., Okada S., Mori H., Niikura H., Omine M., Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkilating agent. Cancer 1995; 75: 471–477
   PubMed Web of Science ®Google Scholar
• Sterkers Y., Proudhomme C., Lai J. L., Demory J. L., Caulier M. T., Wattel E., Bordessoule D., Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndrome followimng essential thrombocythemia. Blood 1998; 91: 616–622
   PubMed Web of Science ®Google Scholar
• Nand S., Stock W., Godwin J., Fisher S. G. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. American Journal Hematology 1996; 52: 42–46
   PubMed Web of Science ®Google Scholar
• Murphy S., Peterson P., Iland H., Laszlo J. Experience of the Polycythemia vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Seminars Hematology 1997; 34: 29–39
   PubMed Web of Science ®Google Scholar
• Randi M. L., Stocco F., Rossi C., Tison T., Girolami A. Thrombosis and hemorrhages in thrombocytosis: evaluation of a large cohort of patients (357 cases). Journal Medicine 1991; 22: 213–223
   PubMedGoogle Scholar
• Chievitz E., Thiede T. Complications and causes of death in polycthemia vera. Acta Medica Scandinava 1963; 172: 513–523
   Web of Science ®Google Scholar
• Lawrence J. H., Winchell H. S., Donald W. G. Leukemia in polycythemia vera. Relationship to splenic myeloid metaplasia and therapeutic radiation dose. Annals Internal Medicine 1969; 70: 763–771
   PubMed Web of Science ®Google Scholar
• Colombi M., Radaelli R., Zocchi L., Maiolo A. T. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926–2930
   PubMed Web of Science ®Google Scholar
• Sedlacek S. M., Curtis J. L., Weintraub J., Levin J. Essential thrombocythemia and leukemic transformation. Medicine 1986; 65: 353–364
   PubMed Web of Science ®Google Scholar
• Groupe Francais de Cytogenetique Hematologique. Cytogenetics of acutely transformed chronic myeloproliferative syndromes without Philadelphia chormosome. A multi-center study of 55 patients. Cancer Genetics Cytogenetics 1988; 32: 157–168
   PubMed Web of Science ®Google Scholar
• Lofvenberg E., Nordenson I., Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxy-urea-treated patients with Philadelphia-chromosome negative chronic myeloproliferative disease. Cancer Genetics Cytogenetics 1990; 49: 57–67
   PubMed Web of Science ®Google Scholar
• Van den Anker-Lugtenburg P. J., Sizzo W. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea. American Journal Hematology 1990; 33: 152
   PubMed Web of Science ®Google Scholar
• Furgerson J. L., Vukelja S. J., Baker W. J., O'Rourke T. J. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. American Journal Hematology 1996; 51: 137–140
   PubMed Web of Science ®Google Scholar
• Kwong Y. L. Leukemic risk in polycythemia vera and essential thrombocythemia. European Journal Haematology 1996; 56: 90–92
   PubMedGoogle Scholar
• Murphy S., Peterson P., Hand H. J., Fruchtman S. Hydroxyurea and other myelosuppressive agents in the treatment of essential thrombocythemia: analysis of leukemogenic potential. Thrombosis Haemostasis 1993; 69: 564a
   Web of Science ®Google Scholar
• Berkhan L. C., Nelson J., Ockelfors P. A., Browett P. J. Transformation of essential thrombocythemia to acute lymphoblastic leukemia. Leukemia Lymphoma 1996; 20: 347
   PubMed Web of Science ®Google Scholar
• Liozon E., Brigaudeau C., Trimoreau F., Desangles F., Fermeaux V., Praloran V., Bordessoule D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature. Hematology Cell Therapy 1997; 39: 11–18
   PubMedGoogle Scholar
• Ferrari D., Ticozzelli G., De Vizzi M., Corigliano P., De Vizzi G. Essential thrombocythemia and acute leukemia. Haematologica 1993; 78: 401
   PubMed Web of Science ®Google Scholar
• Weinfield A., Swolin B., Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukemogenicity with therapeutic implications. European Journal Haematology 1994; 52: 134–139
   PubMed Web of Science ®Google Scholar
• Turlure P., La Prise P. Y., Letortorec S., Linassier C., Ifrah N., Desablens B., Tourani J. M., Lejeune F., Sensebe J. B. Essential thrombocythemia. Clinical course and results of a multicenter prospective study. Blood 1993; 82: 197a
   Web of Science ®Google Scholar
• Peterson P., Murphy S., Iland H. J., Geller S. A., Ellis J. T. Occurrence of acute leukemia in treated essential thrombocythemia. Laboratory Investigations 1994; 70: 118A
   Web of Science ®Google Scholar
• Bellucci S., Janvier M., Tobelem G., Flandrin G., Charpak Y., Berger R., Boiron M. Essential thrombocythemias: clinical evolutionary and biological data. Cancer 1986; 58: 2440–2447
   PubMed Web of Science ®Google Scholar
• Randi M. L., Fabris F., Varotto L., Rossi C., Macri C., Girolami A. Hematological complications in polycythemia vera and thrombocythemia patients treated with radiophosphorus (32P). Folia Hematologica 1990; 3: 462–467
   Google Scholar
• Najean Y., Rain J. D. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Seminars in Hematology 1997; 34: 6–16
   PubMed Web of Science ®Google Scholar
• Aul C., Bowen D. T., Yoshida Y. Pathogenesis, ethnology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83: 71–86
   PubMed Web of Science ®Google Scholar
• Jary L., Massafa H., Fourcade C., Genet P., Pulik M., Flaudrin G. The 17p-syndrome: a distinct myelodysplastic syndrome entity. Leukemia Lymphoma 1997; 25: 163–168
   PubMed Web of Science ®Google Scholar
• Ruggeri M., Finazzi G., Tosetto A., Riva S., Rodeghiero F., Barbui T. No treatment for low risk thrombo-cythemia: results of a prospective study. British Journal Haematology 1998; 103: 772–777
   PubMed Web of Science ®Google Scholar